Laurus Labs Ltd.
LAURUSLABS · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹617.09.
Piotroski F-score 7/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%17.7%
- ✓Low debt (D/E < 0.5)0.46x
- ✕Positive free cash flow
- ✕Revenue growth > 10%5%
- ✓Earnings growing19%
- ✓Net margin ≥ 10%13.0%
- ✕Current ratio > 1.51.33
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 10.24
- ✓Piotroski ≥ 77/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Financially solid — Altman Z 10.24.
- •High Piotroski quality score (7/9).
Opportunities
- •Earnings growing (19% YoY).
Threats
- •Rich valuation versus sector peers.
- •Trades ~45% above our estimated fair value.
About Laurus Labs Ltd.
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary suppleme
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.